CDK1/2/4-IN-1 (compound 3a) is a potent CDK inhibitor with IC50 values of 1.47, 0.78, and 0.87 μM for CDK1, CDK2, and CDK4, respectively. It can be used in cancer research to arrest the cell cycle at the G2/M phase and induce apoptosis, elevating Bax, caspase-3, and P53 levels while decreasing Bcl-2 levels [1].

CDK1/2/4-IN-1 (compound 3a), at concentrations between 0.01 and 100 μM over 24 hours, shows antitumor activity in multiple cancer cell lines, including HepG-2 (liver cancer), A549 (lung cancer), and MCF-7 (breast cancer), with IC50 values of 1.56, 1.39, and 1.97 μM respectively [1]. In A549 cells treated with 1.39 μM for 24 hours, it induces G2/M phase cell cycle arrest, apoptosis, and the up-regulation of Bax, caspases-3, p53, and the Bcl-2 ratio [1]. A 2.6-fold increase in the G2/M phase and a significant rise in apoptotic cells confirm the compound's efficacy in promoting cell death and inhibiting cancer cell proliferation [1].